Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

Generation of candidate human influenza vaccine strains in cell culture - rehearsing the European response to an H7N1 pandemic threat.

Whiteley A, Major D, Legastelois I, Campitelli L, Donatelli I, Thompson CI, Zambon MC, Wood JM, Barclay WS.

Influenza Other Respir Viruses. 2007 Jul;1(4):157-66. doi: 10.1111/j.1750-2659.2007.00022.x.

2.

A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults.

Karron RA, Callahan K, Luke C, Thumar B, McAuliffe J, Schappell E, Joseph T, Coelingh K, Jin H, Kemble G, Murphy BR, Subbarao K.

J Infect Dis. 2009 Mar 1;199(5):711-6. doi: 10.1086/596558.

3.

A live attenuated cold-adapted influenza A H7N3 virus vaccine provides protection against homologous and heterologous H7 viruses in mice and ferrets.

Joseph T, McAuliffe J, Lu B, Vogel L, Swayne D, Jin H, Kemble G, Subbarao K.

Virology. 2008 Aug 15;378(1):123-32. doi: 10.1016/j.virol.2008.05.021. Epub 2008 Jun 27.

4.

FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, Bethesda, Maryland, US, December 10-11, 2007.

Eichelberger M, Golding H, Hess M, Weir J, Subbarao K, Luke CJ, Friede M, Wood D.

Vaccine. 2008 Aug 12;26(34):4299-303. doi: 10.1016/j.vaccine.2008.06.012. Epub 2008 Jun 26.

PMID:
18582523
5.

Vaccines: correlates of vaccine-induced immunity.

Plotkin SA.

Clin Infect Dis. 2008 Aug 1;47(3):401-9. doi: 10.1086/589862. Review.

PMID:
18558875
6.
7.

Role of interferon in the replication of human parainfluenza virus type 1 wild type and mutant viruses in human ciliated airway epithelium.

Bartlett EJ, Hennessey M, Skiadopoulos MH, Schmidt AC, Collins PL, Murphy BR, Pickles RJ.

J Virol. 2008 Aug;82(16):8059-70. doi: 10.1128/JVI.02263-07. Epub 2008 Jun 4.

8.

Contemporary North American influenza H7 viruses possess human receptor specificity: Implications for virus transmissibility.

Belser JA, Blixt O, Chen LM, Pappas C, Maines TR, Van Hoeven N, Donis R, Busch J, McBride R, Paulson JC, Katz JM, Tumpey TM.

Proc Natl Acad Sci U S A. 2008 May 27;105(21):7558-63. doi: 10.1073/pnas.0801259105. Epub 2008 May 27.

9.

Protection of chickens against avian influenza with non-replicating adenovirus-vectored vaccine.

Toro H, Tang DC, Suarez DL, Zhang J, Shi Z.

Vaccine. 2008 May 19;26(21):2640-6. doi: 10.1016/j.vaccine.2008.02.056. Epub 2008 Mar 17.

10.

A vaccine prepared from a non-pathogenic H7N7 virus isolated from natural reservoir conferred protective immunity against the challenge with lethal dose of highly pathogenic avian influenza virus in chickens.

Sakabe S, Sakoda Y, Haraguchi Y, Isoda N, Soda K, Takakuwa H, Saijo K, Sawata A, Kume K, Hagiwara J, Tuchiya K, Lin Z, Sakamoto R, Imamura T, Sasaki T, Kokumai N, Kawaoka Y, Kida H.

Vaccine. 2008 Apr 16;26(17):2127-34. doi: 10.1016/j.vaccine.2008.02.001. Epub 2008 Feb 22.

PMID:
18346824
11.

Development of Eurasian H7N7/PR8 high growth reassortant virus for clinical evaluation as an inactivated pandemic influenza vaccine.

Jadhao SJ, Achenbach J, Swayne DE, Donis R, Cox N, Matsuoka Y.

Vaccine. 2008 Mar 25;26(14):1742-50. doi: 10.1016/j.vaccine.2008.01.036. Epub 2008 Feb 13.

PMID:
18336962
12.

Development and evaluation of an Influenza virus subtype H7N2 vaccine candidate for pandemic preparedness.

Pappas C, Matsuoka Y, Swayne DE, Donis RO.

Clin Vaccine Immunol. 2007 Nov;14(11):1425-32. Epub 2007 Oct 3.

13.

Infection due to 3 avian influenza subtypes in United States veterinarians.

Myers KP, Setterquist SF, Capuano AW, Gray GC.

Clin Infect Dis. 2007 Jul 1;45(1):4-9. Epub 2007 May 24.

14.

Importance of a prime-boost DNA/protein vaccination to protect chickens against low-pathogenic H7 avian influenza infection.

Le Gall-Reculé G, Cherbonnel M, Pelotte N, Blanchard P, Morin Y, Jestin V.

Avian Dis. 2007 Mar;51(1 Suppl):490-4.

PMID:
17494616
15.
16.

Prevalence of neutropenia in the U.S. population: age, sex, smoking status, and ethnic differences.

Hsieh MM, Everhart JE, Byrd-Holt DD, Tisdale JF, Rodgers GP.

Ann Intern Med. 2007 Apr 3;146(7):486-92.

PMID:
17404350
17.

Scientific barriers to developing vaccines against avian influenza viruses.

Subbarao K, Joseph T.

Nat Rev Immunol. 2007 Apr;7(4):267-78. Review.

PMID:
17363960
18.

Live attenuated versus inactivated influenza vaccine in infants and young children.

Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, Kemble G, Connor EM; CAIV-T Comparative Efficacy Study Group.

N Engl J Med. 2007 Feb 15;356(7):685-96. Erratum in: N Engl J Med. 2007 Mar 22;356(12):1283.

19.

Three Indonesian clusters of H5N1 virus infection in 2005.

Kandun IN, Wibisono H, Sedyaningsih ER, Yusharmen, Hadisoedarsuno W, Purba W, Santoso H, Septiawati C, Tresnaningsih E, Heriyanto B, Yuwono D, Harun S, Soeroso S, Giriputra S, Blair PJ, Jeremijenko A, Kosasih H, Putnam SD, Samaan G, Silitonga M, Chan KH, Poon LL, Lim W, Klimov A, Lindstrom S, Guan Y, Donis R, Katz J, Cox N, Peiris M, Uyeki TM.

N Engl J Med. 2006 Nov 23;355(21):2186-94.

20.

Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines.

Sasaki S, Jaimes MC, Holmes TH, Dekker CL, Mahmood K, Kemble GW, Arvin AM, Greenberg HB.

J Virol. 2007 Jan;81(1):215-28. Epub 2006 Oct 18.

Supplemental Content

Support Center